Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 22

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 22
---
 The incurrence of
indebtedness could result in increased fixed payment obligations, and we may be required to agree to certain restrictive covenants, such
as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property
rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to
seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable, and we
may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us,
any of which may have a material adverse effect on our business, operating results and prospects. Even if we believe that we have sufficient
funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific
strategic considerations.

If we are unable to obtain
funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development
programs or the development or commercialization, if any, of our Gelrin hydrogel platform and any future product candidates, or any other
product candidates or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could
materially affect our business, financial condition and results of operations.

Our financial statements contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all.

As described in Note 1c of
our accompanying financial statements, our audited financial statements as of December 31, 2023, contain an explanatory paragraph regarding
substantial doubt about our ability to continue as a going concern. This going concern opinion could materially limit our ability to
raise additional funds through the issuance of equity or debt securities or otherwise. Further financial statements may include an explanatory
paragraph with respect to our ability to continue as a going concern. Until we can generate significant recurring revenues, we expect
to satisfy our future cash needs through debt or equity financing. We cannot be certain that additional funding will be available to
us on acceptable terms, if at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate research
or development plans for, or commercialization efforts with respect to our products. This may raise substantial doubts about our ability
to continue as a going concern.

<div align='center